-

Kit Check Adds General Counsel to Support Continuous Strategic Growth

Attorney Mialeeka Williams-Bibbs joins Kit Check team amid company’s push to continue to revolutionize the medication supply chain

WASHINGTON--(BUSINESS WIRE)--Kit Check™, the leader in automated and intelligent medication management solutions, today announced the appointment of Mialeeka Williams-Bibbs, JD, CCEP, as the company’s first general counsel to help foster Kit Check’s continuous and strategic growth as it expands its client and partner roster. The appointment strengthens the company’s commitment to outstanding customer service and complying with federal regulations, and also amplifies its continued efforts to decrease drug diversion within hospitals.

A registered patent attorney and an active member of the Virginia, Maryland, District of Columbia, and Georgia state bars, Williams comes to Kit Check with over 20 years of legal and business consulting experience across healthcare, healthcare IT, technology, pharmaceuticals, chemicals, consumer products and other sectors. Most recently, she worked with Engage Partners Inc., providing executive level counsel in the healthcare IT space. Over the course of her robust career, Williams has also served as director of innovation intellectual property counsel at The Coca-Cola Company, and chief counsel for the U.S. pharmaceutical hospitals segment at McKesson Corporation.

“We’re thrilled to have Mia join Kit Check as a fully immersed part of the team,” said Kevin MacDonald, CEO and co-founder of Kit Check. “As the company continues to enjoy steady growth, it’s critical to have legal counsel with a deep understanding of our industry who can provide expert guidance as we move forward with implementing Kit Check solutions in more hospitals across the country. By bringing on experienced, strategic individuals like Mia, we can better prevent drug diversion and keep patients and our communities safe.”

At Kit Check, Williams will primarily deal with contract negotiations, interpreting contract language, intellectual property strategy, and ensure the organization and its products are up-to-date with the latest compliance regulations. This will allow the company to be nimbler in spotting, securing and negotiating deals to implement Kit Check solutions with more hospitals and industry partners.

“I’m excited to join Kit Check, as we share the vision of using innovative technology to help keep providers and patients safe,” said Williams. “I’m looking forward to adding significant value to the company, especially in supporting its core mission of combating drug diversion. With my open-door policy, I also hope to foster an internal culture of comfort when it comes to discussing legal questions, ensuring all Kit Check employees are equipped with the most relevant, pertinent legal information available and leading to continued exceptional customer service and expansion capabilities.”

Williams earned a J.D. from George Washington University Law School and a B.S. in chemical engineering from Howard University. She was born and raised in Compton, Calif., and will be relocating to Washington, DC, after living in Atlanta for the last 13 years.

About Kit Check®

Kit Check is the leading provider of automated medication tracking and diversion detection solutions for hospital pharmacies in the U.S., bringing visibility, simplicity, and predictability to the complex world of medication supply management. Our groundbreaking medication intelligence platforms provide item level visibility, workflow simplicity and actionable analytics, empowering stakeholders to deliver the right medicine to the right patient at the right time, every time. To date, our more than 500 U.S. and Canadian hospital partners have tracked more than 100 million medications using Kit Check’s RFID product. Bluesight™ for Controlled Substances software is currently in use in more than 100 hospitals including full health system implementations, with more than 11 million cases tracked, and was ranked #1 in the Drug Diversion Monitoring category in the 2019 Best in KLAS report. More information about Kit Check and our software solutions can be found at kitcheck.com.

Contacts

Jill Gross
Matter Health for Kit Check
kitcheck@matternow.com

Kit Check


Release Summary
Attorney Mialeeka Williams-Bibbs has joined the Kit Check team amid company’s push to continue to revolutionize the medication supply chain
Release Versions

Contacts

Jill Gross
Matter Health for Kit Check
kitcheck@matternow.com

More News From Kit Check

New Report from BluesightⓇ Sheds Light on U.S. Consumer Trust in Healthcare and Pharmaceutical Management

ALEXANDRIA, Va.--(BUSINESS WIRE)--BluesightⓇ, The Medication Intelligence™ Company, today published the results of a recent survey measuring U.S. consumers’ trust in the U.S. healthcare system and pharmaceutical industry, which revealed that trust in both is below average. The study also explored how prior knowledge about drug diversion – among other factors – may impact patient perception and decisions about where to seek care. “Through our suite of software solutions, Bluesight aims to provid...

Medication Intelligence Leader Kit CheckⓇ Rebrands as BluesightⓇ

LAS VEGAS--(BUSINESS WIRE)--Kit Check today announced that it has rebranded as BluesightⓇ, The Medication Intelligence™ Company, to reflect its comprehensive suite of software solutions, maintaining its commitment to helping hospitals better serve their patients and pursuing a future where the medication supply chain is more efficient and connected. Founded in 2011, Bluesight provides unit-level visibility of pharmaceutical products from manufacturing plant to patient, addressing challenges suc...

Kit Check Partners with Genixus™ to Introduce RFID-Tagged Propofol as the First Product Within the KinetiX™ Line of Ready-to-Administer Syringes

ALEXANDRIA, Va.--(BUSINESS WIRE)--Kit Check, the leading automation vendor in Medication Intelligence™, today announced that its proprietary Radio Frequency Identification (RFID) technology will be incorporated in the new KinetiX™ Propofol syringes being developed by Genixus™, a pharmaceutical company and FDA-registered repackager and 503B outsourcing provider focused on transforming acute and critical care medicines. Propofol is one of the most commonly used products in hospitals and health sy...
Back to Newsroom